2015 Annual Meeting | 2HC.001 - Infectious, Paraneoplastic, Autoimmune? Diagnosis and Treatment of Rapidly Progressive Encephalopathies

Date Sunday 04/19/15

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��

Topic(s) Neuro-oncology

Learning Objectives Participants should become familiar with the differential diagnosis of infectious, autoimmune, and paraneoplastic encephalopathies, the rational use of antibody testing and infectious disease diagnostics in encephalitis, and strategies for using immunosuppression as empiric treatment for autoimmune and paraneoplastic encephalitis.

CME Available 3.75 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Tracks Subspecialty in Focus

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Didactic

Event Timeline
08:00 AM - 08:10 AM		Introduction Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��
08:10 AM - 08:50 AM		Diagnosis and Management of Acute Viral Encephalitis Kenneth L. Tyler, MD, F�鶹��ýӳ��
08:50 AM - 09:05 AM		Questions and Answers Kenneth L. Tyler, MD, F�鶹��ýӳ��
09:05 AM - 09:45 AM		Paraneoplastic Encephalitis Sean J. Pittock, MD, F�鶹��ýӳ��
09:45 AM - 10:00 AM		Questions and Answers Sean J. Pittock, MD, F�鶹��ýӳ��
10:00 AM - 10:15 AM		Break
10:15 AM - 10:55 AM		Autoimmune Encephalitis Josep O. Dalmau, MD, PhD, F�鶹��ýӳ��
10:55 AM - 11:10 AM		Questions and Answers Josep O. Dalmau, MD, PhD, F�鶹��ýӳ��
11:10 AM - 11:45 AM		Immunosuppression for Treatment of Autoimmune and Paraneoplastic Encephalopathies Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��
11:50 AM - 12:00 PM		Questions and Answers Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��

Faculty Disclosures
Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��	Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to �鶹��ýӳ�� interests or activities.
Sean J. Pittock, MD, F�鶹��ýӳ��	Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Josep O. Dalmau, MD, PhD, F�鶹��ýӳ��	Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for �鶹��ýӳ��. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
Kenneth L. Tyler, MD, F�鶹��ýӳ��	Dr. Tyler has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Protagonist Therapeutics, Newark CA. Dr. Tyler has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Neurological Association/Wiley. Dr. Tyler has received intellectual property interests from a discovery or technology relating to health care. Dr. Tyler has received publishing royalties from a publication relating to health care. Dr. Tyler has a non-compensated relationship as a Director (ex officio) with American Neurological association that is relevant to �鶹��ýӳ�� interests or activities. Dr. Tyler has a non-compensated relationship as a Director with International Society for Neurovirology that is relevant to �鶹��ýӳ�� interests or activities.